Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118717 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL28752404 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL28591949 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL28366372 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21617316 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL21419884 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL29016126 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL14778640 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL9173378 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL252664 | 1.00 | KDM4E (0.63) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116242-B1 | NEW PHARMACEUTICAL COMPOSITION | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2016-10-12 | — | — | EP | claimed |
| US-8138214-B2 | Pharmaceutical composition | SHANGHAI ALLIST PHARMACEUTICAL, INC. (CN) | 2012-03-20 | — | — | US | claimed |
| US-20090326025-A1 | NEW PHARMACEUTICAL COMPOSITION | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2009-12-31 | — | — | US | claimed |
| EP-2116242-A1 | NEW PHARMACEUTICAL COMPOSITION | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2009-11-11 | — | — | EP | claimed |
| CN-117599029-A | Compositions for controlled release of cysteamine and systematic treatment of cysteamine-sensitive disorders | 硫创治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023198197-A1 | FREE-STATE PLX5622 CRYSTAL FORM AND PREPARATION METHOD THEREFOR | 上海皓鸿生物医药科技有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-20160022661-A1 | Dosage Form Comprising Crizotinib | RATIOPHARM GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| EP-2968167-A1 | DOSAGE FORM COMPRISING CRIZOTINIB | ratiopharm GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140159-A1 | DOSAGE FORM COMPRISING CRIZOTINIB | RATIOPHARM GMBH (DE) | 2014-09-18 | — | — | WO | disclosed |
| CN-101022787-B | Abuse-resistant oral dosage form comprising (1R,2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol | GRUENENTHAL GMBH | 2012-01-11 | — | — | CN | disclosed |
| CN-101835474-A | Idarubicin for the treatment of lymphoma in dogs | PFIZER PROD INC | 2010-09-15 | — | — | CN | disclosed |
| CN-100355457-C | Dispersible pharmaceutical compositions | PHARMACIA & UPJOHN CO LLC (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-101022787-A | Abuse-resistant oral dosage form comprising (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol | GRUENENTHAL CHEMIE (DE) | 2007-08-22 | — | — | CN | disclosed |
| CN-1720065-A | Dispersible pharmaceutical compositions | PHARMACIA & UPJOHN CO LLC (US) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326025-A1 | NEW PHARMACEUTICAL COMPOSITION | MYO1G, PEAK1, MYLK2 | KDM4E 575/4885DUSP3 3905/4885MEN1 3681/4885 |
| US-20160022661-A1 | Dosage Form Comprising Crizotinib | ALK, ABL1, FGFR2 | KDM4E 1922/4885DUSP3 3854/4885MEN1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.